Donor-Derived Cell-Free DNA for the Detection of Heart Allograft Injury: The Impact of the Timing of the Liquid Biopsy
Open Access
- 21 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 35 (1) , 10122
Abstract
Background: In heart transplant recipients, donor-derived cell-free DNA (ddcfDNA) is a potential biomarker for acute rejection (AR), in that increased values may indicate rejection. For the assessment of ddcfDNA as new biomarker for rejection, blood plasma sampling around the endomyocardial biopsy (EMB) seems a practical approach. To evaluate the effect of the EMB procedure on ddcfDNA values, ddcfDNA values before the EMB were pairwise compared to ddcfDNA values after the EMB. We aimed at evaluating whether it matters whether the ddcfDNA sampling is done before or after the EMB-procedure.Methods: Plasma samples from heart transplant recipients were obtained pre-EMB and post-EMB. A droplet digital PCR method was used for measuring ddcfDNA, making use of single-nucleotide polymorphisms that allowed both relative quantification, as well as absolute quantification of ddcfDNA.Results: Pairwise comparison of ddcfDNA values pre-EMB with post-EMB samples (n = 113) showed significantly increased ddcfDNA concentrations and ddcfDNA% in post-EMB samples: an average 1.28-fold increase in ddcfDNA concentrations and a 1.31-fold increase in ddcfDNA% was observed (p = 0.007 and p = 0.03, respectively).Conclusion: The EMB procedure causes iatrogenic injury to the allograft that results in an increase in ddcfDNA% and ddcfDNA concentrations. For the assessment of ddcfDNA as marker for AR, collection of plasma samples before the EMB procedure is therefore essential.Keywords
This publication has 18 references indexed in Scilit:
- Liquid biopsies come of age: towards implementation of circulating tumour DNANature Reviews Cancer, 2017
- Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant RecipientsThe Journal of Molecular Diagnostics, 2016
- Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-OriginCell, 2016
- The Role of Cell-Free Plasma DNA in Critically Ill Patients with SepsisBlood Purification, 2015
- Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant RejectionScience Translational Medicine, 2014
- Direct Quantification of Cell-Free, Circulating DNA from Unpurified PlasmaPLOS ONE, 2014
- The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantationThe Journal of Heart and Lung Transplantation, 2013
- Complications of Endomyocardial Biopsy in Heart Transplant Patients: A Retrospective Study of 2117 Consecutive ProceduresTransplantation Proceedings, 2011
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005
- Interobserver variability in the pathologic interpretation of endomyocardial biopsy results.Circulation, 1987